NCT00443157已完成2 期
A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- serum bactericidal antibody
研究概览
简要总结
This study is the third in a series using the MenB vaccine from the National Institute of Public Health in Norway (NIPH). The vaccine was first made in response to a high incidence of disease using the 44/76 strain which was resopnsible for most of the disease there. The VEC did the first study, MNB1, using this vaccine. Since then the NIPH has formed a commercial partnership with Chiron Vaccines and has reformulated the vaccine using the NZ98/254 MenB strain for use in New Zealand.
The vaccine was first produced at NIPH facilties and it was this vaccine that was used in our second study, MNB2. The current study, MNB3, will use the NZ98/254 MenB vaccine but from Chiron facilities where production has been scaled up in order to provide enough doses for the national immunisation campaign that is ongoing in New Zealand.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed written consent given for four immunisations (group 2 will receive 3 doses only) with MeNZB TM vaccine, as well as for eight blood draws to be taken as described in the patient information leaflet in appendix 2
- •Healthy adults (university students) aged 18 up to 40 years on inclusion in the study
排除标准
- •On enrolment:
- •Previous history of bacteriologically confirmed disease caused by N. meningitidis
- •Prior receipt of any group B meningococcal vaccine
- •have had household contact with and/or intimate exposure to an individual with culture or PCR proven N. meningitidis serogroup B within the previous 60 days
- •have either received, or for whom there is intent to immunize with, any vaccines or investigational agents within 50 days prior to enrolment, through to 50 days following the last study vaccine administration, with the exception of influenza vaccines or post-exposure tetanus vaccination
- •have a history of any anaphylactic shock, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component
- •have experienced significant acute or chronic infections requiring systemic antibiotic treatment within the past 14 days
- •have any present or suspected serious acute or chronic disease such as: cardiac or autoimmune disease, insulin dependent diabetes or progressive neurological disease or severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease; leukaemia, lymphomas, neoplasm;
- •have a known or suspected impairment of the immune function, or those receiving immunosuppressive therapy, or having received immunosuppressive therapy, including systemic steroids, or ACTH or inhaled steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis suppression;
- •have received blood, blood products or a parenteral immunoglobulin preparation in the past 12 weeks;
- •have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;
- •have a history of seizure disorder;
- •have an inherited genetic anomaly (known cytogenic disorders) e.g., Down's syndrome;
- •Language difficulty sufficient to preclude adequate comprehension of the information sheet, consent form or study nurse's explanation of the study;
- •The possibility of pregnancy - a pregnancy test (urine) on the scheduled day of vaccination will be offered to any female wishing to participate in the study. A positive test will result in exclusion from the study. (Agreement from each female participants will be sought prior to vaccination that they will take adequate precautions to avoid pregnancy for the duration of the vaccination phase of the study until the final blood sample appointment following their final vaccination, i.e. until the week 63 - visit 8 - blood appointment);
- •Current regimen of chronic prescription medications other than oral contraceptives, or current regular use of any over-the-counter concomitant medications including antipyretics and non-steroidal anti-inflammatory agents;
- •Current participation in any other clinical trial (an undertaking will be sought from participants not to enrol in any other clinical trial for the duration of this study);
- •They have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
- •Current (to be checked prior to each vaccination):
- •Generalised acute systemic illness on the day of immunisation
- •Sublingual temperature >38,5oC on the day of immunisation
- •Development of any condition specified in the initial exclusion criteria cited above will constitute a criterion for exclusion from receiving subsequent vaccine doses.
- •Any serious reaction related to the study vaccines, which in the opinion of the investigator should alter the course of subsequent study.
结局指标
主要结局
serum bactericidal antibody
次要结局
- Serum antibody ELISA
- Opsonophagocytosis assay
- Immunoblotting
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid TumorsH1N1 Influenza VirusInvasive Solid TumorsNCT01031719Chiltern Pesquisa Clinica Ltda59
已完成
3 期
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerAdvanced Metastatic Breast CancerNCT03096847Novartis Pharmaceuticals502
已完成
3 期
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes MellitusH1N1 Influenza VirusChronic Pulmonary DiseaseChronic Heart DiseaseDiabetes MellitusNCT01032395Chiltern Pesquisa Clinica Ltda342
已完成
3 期
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 InfectionH1N1 Influenza VirusHuman Immunodeficiency Virus Type 1 (HIV-1) InfectionNCT01032408Chiltern Pesquisa Clinica Ltda154
已完成
3 期
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01941095Hoffmann-La Roche100